Clinical Partnerships O&O Alpan has a strong track record in clinical trials with strategic partnerships from CROs like Quintiles, suggesting opportunities to propose expanded trial collaborations, enrollment optimization services, or site management support for additional therapeutic areas.

Therapeutic Expansion The expansion into eosinophilic esophagitis and a dedicated lysosomal disorders unit indicates appetite for new indications; potential sales angles include trial recruitment acceleration, database access for niche patient populations, and patient outreach programs.

Leadership & Compliance With Dr. Ozlem Goker-Alpan serving as President and CMO and the site’s established leadership, there is credibility for strategic advisory engagements, investigator-initiated studies, and quality-focused collaborations with sponsors seeking experienced clinical sites.

Tech & Access Reliance on Google Workspace and related tools suggests openness to digital collaboration platforms, remote monitoring, and streamlined study operations; there is potential to pitch integrated study enablement solutions, data management support, and sponsor access optimization.

Financial Footing Revenue in the 1M–10M range and a mid-sized team position O&O Alpan as a cost-effective, capable partner for mid- to late-phase trials or investigator-initiated studies, presenting opportunities to upsell site performance improvements and patient recruitment acceleration services.